

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 5, 2023

---

**Keros Therapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(state or other jurisdiction  
of incorporation)

**001-39264**  
(Commission  
File Number)

**81-1173868**  
(I.R.S. Employer  
Identification No.)

**1050 Waltham Street, Suite 302**  
**Lexington, Massachusetts**  
(Address of principal executive offices)

**02421**  
(Zip Code)

Registrant's telephone number, including area code: (617) 314-6297

Not applicable

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
-

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	KROS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 7.01 Regulation FD Disclosure.**

On September 5, 2023, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing that Jasbir Seehra, the Company's President and Chief Executive Officer, will participate in a fireside chat presentation at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 at 4:15 p.m. Eastern time, a corporate presentation at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023 at 11:00 a.m. Eastern time, and a corporate presentation at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. Eastern time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit</b>	
<b>No.</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press release dated September 5, 2023.</a>
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**KEROS THERAPEUTICS, INC.**

By: /s/ Jasbir Seehra  
Jasbir Seehra, Ph.D.  
Chief Executive Officer

Dated: September 5, 2023

## Keros Therapeutics to Present at Upcoming Healthcare Conferences

**LEXINGTON, Mass., September 5, 2023 (GLOBE NEWSWIRE)** -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF- $\beta$ ") family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Sehra, Ph.D., will present at the following healthcare conferences:

### **Morgan Stanley 21<sup>st</sup> Annual Global Healthcare Conference**

- *Date and Time:* Monday, September 11, 2023 at 4:15 p.m. Eastern time
- *Link:* A live audio webcast will be available at [https://event.webcasts.com/starthere.jsp?ei=1632002&tp\\_key=2ba5cce9ad&tp\\_special=8](https://event.webcasts.com/starthere.jsp?ei=1632002&tp_key=2ba5cce9ad&tp_special=8)
- *Format:* Fireside Chat Presentation

### **H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference**

- *Date and Time:* Wednesday, September 13, 2023 at 11:00 a.m. Eastern time
- *Link:* A live audio webcast will be available at <https://journey.ct.events/view/2f2aea75-6ae9-491d-a40c-c76a4308baa8>
- *Format:* Corporate Presentation

### **2023 Cantor Global Healthcare Conference**

- *Date and Time:* Wednesday, September 27, 2023 at 1:50 p.m. Eastern time
- *Link:* A live audio webcast will be available at <https://wsw.com/webcast/cantor19/kros/2119887>
- *Format:* Corporate Presentation

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at <https://ir.kerostx.com> for up to 90 days following the conclusion of each event.

### **About Keros Therapeutics, Inc.**

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF- $\beta$  family of proteins. We are a leader in understanding the role of the TGF- $\beta$  family of proteins, which are master regulators of the growth, repair and maintenance of blood cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing large and small molecules that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Keros' third

product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' fourth product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy.

**Investor Contact:**

Justin Frantz

[jfrantz@kerostx.com](mailto:jfrantz@kerostx.com)

617-221-6042